TaiMed Biologics

TaiMed Biologics Inc. is a biotechnology company that develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It markets Trogarzo IV infusion and IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody for HIV treatment and prevention that has completed a phase-1 clinical trial, and a combination of TMB-365 and TMB-380, a monoclonal antibody combination therapy for HIV in phase-1b/2a clinical trials, as well as antibody-drug conjugates for cancer treatment. In addition, it offers contract development and manufacturing services, has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355, and authorizes Samsung Biologics to produce TMB-355. Incorporated in 2007, TaiMed Biologics Inc. is headquartered in Taipei, Taiwan.